Alcanza Clinical Research

Accel Research Sites has been selected as a location for two new COVID-19 vaccine trials.

This time with trials running at three locations in two states.

Accel Clinical Services, the parent company of Accel Research Sites, today announced it would be starting two new studies this month. The company will run trials at its Orlando and Lakeland locations in Florida, as well as in Birmingham, Alabama.

“In the race for a vaccine for COVID-19, clinical trials are essential,” said Matt Maxwell, CEO of Accel Research Sites. “Volunteers for those trials are also essential. We are thankful for all who have already participated and are looking forward to giving more people the opportunity to participate in clinical research, while at the same time helping further research in the fight against coronavirus.”

Accel Research Sites seeks to enroll participants who are older, as well as racial and ethnic minorities and those who are at higher risk of being affected by COVID-19 for these trials.

The company is also continuing recruitment for several other ongoing clinical trials for COVID-19 vaccine candidates.

Those interested in participating in the study can visit covidorlando.com. An Accel Research Sites staff member will reach out to further evaluate eligibility.

Accel Research Sites provides novel treatment options in all major therapeutic areas. It has more than 30 locations, including a 62-bed Phase 1 unit in Florida and units in Georgia and Alabama. Accel Research Sites has enrolled more than 12,000 patients in more than 1,000 trials since its inception in 1998.